Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth.
Calda
Pavel
P
Charles University, First Medical School, Obstetrics & Gynecology, Prague, Czech Republic. calda@gynstart.cz
D000077713:17 alpha-Hydroxyprogesterone Caproate; D054316:Biomarkers, Pharmacological / Q000032:analysis*; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000009:adverse effects* / Q000627:therapeutic use*; D007231:Infant, Newborn; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D045167:Progesterone Congeners / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D054316:Biomarkers, Pharmacological; D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate